References
- Bhaumik SK, Singh MK, Karmakar S, De T. UDP-Gal: N-acetylglucosamine beta 1-4 galactosyltransferase expressing live attenuated parasites as vaccine for visceral leishmaniasis. Glycoconj. J. 26(6), 663–673 (2009).
- Handman E. Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 14(2), 229–243 (2001).
- Daneshvar H, Coombs GH, Hagan P, Phillips RS. Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines. J. Infect. Dis. 187(10), 1662–1668 (2003).
- Breton M, Tremblay MJ, Ouellette M, Papadopoulou B. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect. Immun. 73(10), 6372–6382 (2005).
- Silvestre R, Cordeiro-da-Silva A, Santarém N, Vergnes B, Sereno D, Ouaissi A. SIR2-deficient Leishmania infantum induces a defined IFN-gamma/IL-10 pattern that correlates with protection. J. Immunol. 179(5), 3161–3170 (2007).
- Selvapandiyan A, Dey R, Nylen S, Duncan R, Sacks D, Nakhasi HL. Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis. J. Immunol. 183(3), 1813–1820 (2009).
- Birnbaum R, Haskell J, Vanchinathan V et al. Killed but metabolically active Leishmania as a novel whole-cell vaccine for visceral leishmaniasis. Clin. Vaccine Immunol. 19(4), 490–498 (2012).
- Mizbani A, Taheri T, Zahedifard F et al. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine 28(1), 53–62 (2009).
Website
- Hsia R, Wang NE, Halpern J. Leishmaniasis. eMedicine (2006). www.emedicine. com/emerg/topic296.htm